Michael Pritchett, DO
Pulmonary Disease · Pinehurst, NCNPI 1023055761
Payments from drug & device makers
Across 1,761 payments — averaging $1236.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1M
- Galvanize Therapeutics, Inc$287K
- Janssen Research & Development, LLC$283K
- Ethicon Endo-surgery Inc.$130K
- United Therapeutics Corporation$89K
- Actelion Pharmaceuticals, Ltd$67K
- plus $283K from 54 others
What the payments were for
- Consulting fees$191,59214%
- Speaking & faculty fees$700,75553%
- Travel & lodging$111,5718%
- Food & beverage$43,7273%
- Education$274,00321%
- Gifts$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$903,016
- DA VINCI SP$116,500
- TAGRISSO$38,759
- ALIYA SYSTEM$29,619
- UPTRAVI$25,749
- OPSUMIT$22,719
- superDimension$17,721
- CERTUS 140 MICROWAVE ABLATION SYSTEM$11,158
- Monarch Platform$10,178
- ILLUMISITE$8,729
- ION$8,400
- ORENITRAM$5,714
- HealthMyne$5,509
- XALKORI$5,500
- REMODULIN$5,364
- TYVASO$5,364
- NONE$3,920
- IMFINZI$3,202
- ACQUIRE$3,200
- NEUWAVE Flex Microwave Ablation System$1,726
How this compares
$2,177,273 in reported general payments places this provider in the 95th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 11 | $257,112 |
| Tyvaso DpiTreprostinil | 11 | $253,584 |
| OfevNintedanib Esylate | 11 | $147,605 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 11 | $116,553 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 130 | $99,297 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $14,410 |
| Spiriva RespimatTiotropium Bromide | 23 | $11,652 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $10,799 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 21 | $10,133 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $8,318 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $5,253 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 82 | $2,516 |
| Omeprazole | 38 | $320 |
| Prednisone | 49 | $295 |
| Methylprednisolone | 18 | $154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi | $32,167 | $257,11211 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $380 | $169,39055 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $830 | $122,025178 claims |
| Grifols USA, LLCProlastin C | $517 | $116,55311 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $47,804 | $16,05235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Pinehurst
- Adam BelangerPinehurst$338K
- Bradley IcardPinehurst$299K
- Scott SkiboPinehurst$229K
- Selwyn SpangenthalCharlotte$7M
- Thomas SternHuntersville$5.2M
- Laurie SnyderDurham$3.8M
- Scott PalmerDurham$3.8M
- Anup BanerjeeGastonia$2.1M
- Hubert FordChapel Hill$2M
- Murali RamaswamyGreensboro$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.